Header Logo

Connection

SUSAN HILSENBECK to CTLA-4 Antigen

Back to Details
This is a "connection" page, showing publications SUSAN HILSENBECK has written about CTLA-4 Antigen.
SUSAN HILSENBECK
Connection Strength
0.051
CTLA-4 Antigen
  1. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.